PsyBio Therapeutics Corp.
PSYBF
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 0.00% | 0.00% | -100.00% | 0.00% | -98.23% |
| Gross Profit | 0.00% | 0.00% | 100.00% | 0.00% | 98.23% |
| SG&A Expenses | -88.54% | -42.69% | -59.58% | -56.60% | -41.85% |
| Depreciation & Amortization | -- | 0.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -88.33% | -45.46% | -54.07% | -59.92% | -62.23% |
| Operating Income | 88.33% | 45.46% | 54.07% | 59.92% | 62.23% |
| Income Before Tax | 87.34% | 48.81% | 58.92% | 60.27% | 62.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.34% | 48.81% | 58.92% | 60.27% | 62.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.34% | 48.81% | 58.92% | 60.27% | 62.46% |
| EBIT | 88.33% | 45.46% | 54.07% | 59.92% | 62.23% |
| EBITDA | 89.45% | 46.75% | -- | -- | -- |
| EPS Basic | 89.06% | 55.32% | 57.92% | 59.51% | 62.24% |
| Normalized Basic EPS | 89.61% | 51.22% | -10.64% | 59.38% | 63.16% |
| EPS Diluted | 89.06% | 55.32% | 57.92% | 59.51% | 62.24% |
| Normalized Diluted EPS | 89.61% | 51.22% | -10.64% | 59.38% | 63.16% |
| Average Basic Shares Outstanding | 14.55% | 13.74% | -1.64% | -1.78% | -0.97% |
| Average Diluted Shares Outstanding | 14.55% | 13.74% | -1.64% | -1.78% | -0.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |